Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
agenT-797 in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation
NCT07758218Phase 1Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of agenT-797 in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) and 1 more, sponsored by University of Wisconsin–Madison. Primary endpoints: Number Of Participants With Treatment-related Adverse Events and Number Of Dose-limiting Toxicities. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
agenT-797
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07758218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758218.